Catalog No.
Product Name
Application
Product Information
Citations
-
Wnt inhibitor
IWR-1-endo is a potent inhibitor of the Wnt response, blocking a cell-based Wnt/β-catenin pathway reporter response with an IC50 value of 180 nM. Wnt proteins bind to receptors on the cell surface, initiating a signaling cascade that leads to β-catenin activation of gene transcription.- Yuichi Akaba, .et al. , iScience, 2025, Oct 16;28(11):113789 PMID: 41244585
- Charles A.Herring, .et al. , Cell, 2022, Oct 27;S0092-8674(22)01258-2 PMID: 36318921
-
GSK-3 inhibitor
LY2090314 is a potent inhibitor of glycogen synthase kinase-3 (GSK-3) which plays an important role in many pathways, including initiation of protein synthesis, cell proliferation, cell differentiation, and apoptosis.- Yuki Shimizu, .et al. , NPJ Precis Oncol, 2022, Mar 17;6(1):16 PMID: 35301419
-
TGF-β/ALK5 inhibitor
A83-01 is a selective inhibitor of the transforming growth factor-beta type I receptor ALK5, the Nodal receptor ALK4, and the nodal receptor ALK7- Yuko Nagashima, .et al. , Sci Rep, 2026, Feb 25;16(1):7582 PMID: 41741551
- T Usui, .et al. , ResearchSquare, 2026, Feb 22
- Jin-Young Lee, .et al. , Mater Today Bio, 2026, Mar 19;38:103026 PMID: 41953717
- Yuko Nagashima, .et al. , Research Square, 2025, Sep 26
- Yuta Shinohara, .et al. , J Vet Med Sci, 2025, Feb 15;87(2):232-240 PMID: 39756955
- Yuko Nagashima, .et al. , Sci Rep, 2025, Feb 19;15(1):6108 PMID: 39972078
- Masayuki Fukumoto, .et al. , PLoS One, 2024, Dec 5;19(12):e0313312 PMID: 39636897
- Raghda Shahin, .et al. , Drug Metabolism and Pharmacokinetics, 2024, 4 December PMID: 40373539
- Kyunghyun Park, .et al. , Advanced Therapeutics, 2024, 7(6)
- Yuko Nagashima, .et al. , Research Square, 2024, June 4th
- Shota Mizuno, .et al. , Biol Pharm Bull, 2024, 47(1):120-129 PMID: 38171772
- Andreea Manole, .et al. , Cell Rep, 2023, Dec 26;42(12):113466 PMID: 38039131
- Claudia Z Han, .et al. , Immunity, 2023, Sep 12;56(9):2152-2171 PMID: 37582369
- Yomogi Shiota Sato, .et al. , Biomed Pharmacother, 2023, Sep;165:115079 PMID: 37413906
- Yomogi Sato, .et al. , Biomed Pharmacother, 2023, Jun;162:114651 PMID: 37030135
- Dan Zhao, .et al. , Poult Sci, 2022, Mar; 101(3): 101642 PMID: 35016046
- Anna Nakanishi, .et al. , Regen Ther, 2022, Sep 9;21:351-361 PMID: 36161099
- Amira Abugomaa, .et al. , Biomed Pharmacother, 2022, Oct;154:113597 PMID: 36030590
- Isamu Ogawa, .et al. , Biomaterials, 2022, Sep;288:121696 PMID: 36038421
- Mohamed Elbadawy, .et al. , Cancer Biol Ther, 2021, Jun 3;22(5-6):357-371 PMID: 34034619
- Mohamed Elbadawy, .et al. , Authorea, 2020, October 20
- Daichi Onozato, .et al. , Biol Pharm Bull, 2020, 43(7), 1088-1095 PMID: 32612071
- Amira Abugomaa, .et al. , Sci Rep, 2020, Jun 10;10(1):9393 PMID: 32523078
- Jing-Yu Lin, .et al. , Cell Discov, 2020, 6: 20 PMID: 32284878
- Kondo S, .et al. , Biol Open, 2020, Jan 9;9(1) PMID: 31919043
- Onozato D, .et al. , Drug Metab Dispos, 2018, Nov;46(11):1572-1580 PMID: 29615438
- Usui T, .et al. , Curr Protoc Toxicol, 2018, Feb 21;75:22.6.1-22.6.7 PMID: 29512123
- Kondo S, .et al. , Inflamm Res, 2018, Dec;67(11-12):975-984 PMID: 30317465
- Onozato D, .et al. , Stem Cells Dev, 2018, Aug 1;27(15):1033-1045 PMID: 29742964
- Tatsuya Usui, .et al. , Int J Mol Sci, 2018, Apr; 19(4): 1098 PMID: 29642386
- Tatsuya Usui, .et al. , Cancer Sci, 2017, Dec; 108(12): 2383-2392 PMID: 29024204
- Tatsuya Usui, .et al. , Physiol Rep, 2017, Jun; 5(12): e13318 PMID: 28642339
- Tatsuya Usui, .et al. , Stem Cells Int, 2016, 2016: 7053872 PMID: 28119740
-
GSK-3β Inhibitor
Manzamine A is a selective inhibitor of glycogen synthase kinase 3 beta (GSK-3β) and cyclin-dependent kinase 5 (CDK-5), with respective IC50 values of 10.2 μM and 1.5 μM. This compound exhibits significant biological activity, including antimalarial and anticancer effects, and has been shown to inhibit autophagy in pancreatic cancer cells by targeting vacuolar ATPases. Additionally, Manzamine A demonstrates potent antiviral properties against herpes simplex virus type 1 (HSV-1), making it a valuable reagent for diverse research applications in cancer, autophagy, and virology studies. -
Stable Isotope
5-Azacytidine-15N4 is a stable isotope-labeled version of 5-Azacytidine, featuring both 13C and 15N isotopes. As a nucleoside analogue of cytidine, 5-Azacytidine specifically inhibits DNA methylation by being incorporated into DNA, thereby covalently trapping DNA methyltransferases. This process contributes to the reversal of epigenetic modifications. Additionally, 5-Azacytidine has been shown to induce autophagy in cells, making it valuable for research in epigenetics and cellular metabolism. -
GSK-3β Inhibitor
Manzamine A hydrochloride is an orally active beta-carboline alkaloid that specifically inhibits GSK-3β and CDK-5, with IC50 values of 10.2 μM and 1.5 μM, respectively. This compound demonstrates significant antimalarial and anticancer properties, with additional effects such as inhibiting vacuolar ATPases and autophagy processes in pancreatic cancer cells. Furthermore, Manzamine A hydrochloride exhibits potent activity against HSV-1, making it valuable for various research applications in cancer biology and virology. -
PKG Inhibitor
Protein kinase G inhibitor-1 is a selective inhibitor targeting protein kinase G (PKG) with an IC50 of 0.9 μM. This compound is utilized primarily in research related to mycobacterial infections, providing insights into the mechanisms of pathogenesis and potential therapeutic approaches. Its efficacy in inhibiting PKG activity makes it a valuable tool for exploring mycobacterial biology and developing novel treatments. -
WNT7A Inhibitor/Photosensitizer
WNT7A-IN-1 sodium is a selective inhibitor of WNT7A that disrupts the interaction between WNT7A and its receptor FZD5, leading to enhanced expression of MHC-I. This reagent is known to significantly increase levels of MHC-I and phosphorylated p65 while decreasing active β-catenin expression. Additionally, WNT7A-IN-1 sodium acts as a photosensitizer in the green spectral region, making it suitable for applications in photodynamic therapy and immunological studies. -
Hedgehog Inhibitor
Hedgehog IN-9 is a potent Hedgehog inhibitor that primarily targets the inhibition of GLI1 expression. It has been shown to enhance BRD2 protein levels in cells and effectively inhibit the growth of medulloblastoma spheroid cells. Additionally, Hedgehog IN-9 can be utilized for the synthesis of photoaffinity labeling probes, making it a valuable tool in cancer research and related biochemical applications. -
CDK/GSK3β/JNK Inhibitor
Indirubin-3′-oxime (IDR3O) is a synthetic derivative of indirubin that functions as a potent inhibitor of cyclin-dependent kinases (CDKs), glycogen synthase kinase 3β (GSK3β), and all three isoforms of c-Jun N-terminal kinases (JNK1, JNK2, JNK3). It demonstrates inhibitory activity with IC50 values of 0.8 μM, 1.4 μM, and 1.0 μM for each JNK isoform, respectively. Indirubin-3′-oxime is also known to promote chondrocyte height growth through the activation of Wnt/β-catenin signaling, making it relevant for studies in cellular growth and differentiation. -
GSK-3β Inhibitor
GSK-3β inhibitor 13 is a potent inhibitor of glycogen synthase kinase 3 beta (GSK-3β) and GSK-3α, demonstrating IC50 values of 0.73 nM and 0.35 nM respectively. This orally active compound exhibits blood-brain barrier permeability and effectively reduces tau phosphorylation, with an IC50 of 58 nM. Its ability to modulate tau phosphorylation makes it valuable for research focused on neurodegenerative disorders, particularly Alzheimer's disease, by potentially mitigating the formation of neurofibrillary tangles. -
Wnt Agonist
Wnt/β-catenin agonist 4 (Derivative 83) is a potent agonist of the Wnt signaling pathway that stimulates Wnt/β-catenin signal transmission. This compound plays a crucial role in enhancing cellular processes regulated by Wnt signaling, such as cell proliferation, differentiation, and tissue regeneration. It is useful in various research applications, including studies on developmental biology, cancer progression, and regenerative medicine. -
Wnt Activator
Dalosirvat is a potent Wnt activator that effectively enhances Wnt signaling pathways. With an EC50 of 28-29 nM, it demonstrates significant biological activity in promoting cell proliferation and differentiation in various contexts. This compound is primarily utilized in research applications related to developmental biology, cancer research, and regenerative medicine, facilitating investigations into the roles of Wnt signaling in cellular processes. -
Wnt Inhibitor
Wnt Pathway Inhibitor 3 is a potent inhibitor of the Wnt signaling pathway, exhibiting an IC50 value of 45 nM. This compound demonstrates significant antiproliferative activity, making it a valuable tool for research in cancer biology and developmental studies. Its ability to modulate Wnt signaling can aid in the exploration of various cellular processes and disease mechanisms. -
Wnt Signaling Inhibitor
JW67 is a potent Wnt signaling inhibitor that targets the multiprotein complex composed of β-catenin, GSK-3β, AXIN, APC, and CK1, demonstrating an IC50 of 1.17 µM. By effectively reducing active β-catenin levels, JW67 leads to the downregulation of Wnt target genes, making it a valuable tool for studying Wnt signaling pathways. Additionally, JW67 inhibits the growth of colorectal cancer cells, providing potential applications in cancer research and therapeutic development. -
Wnt Activator
Wnt Pathway Activator 2 is a potent activator of the Wnt signaling pathway, exhibiting an EC50 value of 13 nM. This compound promotes Wnt pathway activation, making it a valuable tool for researching developmental biology and cancer progression. Its ability to modulate Wnt signaling can facilitate studies on cellular processes such as proliferation, differentiation, and stem cell biology. -
Wnt Inhibitor
Ipafricept is a recombinant fusion protein that functions as a Wnt inhibitor by binding to Wnt ligands via the extracellular portion of the human Frizzled-8 receptor fused with a human IgG1 Fc fragment. This mechanism effectively blocks Wnt signaling pathways, leading to reduced tumor growth and decreased liver and lung metastases when combined with Gemcitabine in pancreatic cancer mouse models. Additionally, Ipafricept demonstrates significant inhibitory activity against solid tumors, including desmoid tumor, germ cell cancer, and ovarian cancer, with an acceptable tolerance profile. -
Wnt Signaling Inhibitor
Coronaridine is an iboga alkaloid that functions as a Wnt signaling pathway inhibitor, effectively reducing β-catenin expression. This compound is primarily employed in research related to cancer biology, stem cell differentiation, and developmental processes, where dysregulation of the Wnt pathway is implicated. Its ability to modulate β-catenin levels makes it a valuable tool for investigating the mechanistic roles of Wnt signaling in various biological contexts. -
Wnt Inhibitor
WIC1 is a potent Wnt signaling inhibitor that targets the Wnt pathway, crucial for various biological processes, including cell proliferation and differentiation. This compound demonstrates significant anti-cancer activity by disrupting Wnt-mediated transcriptional activation, making it valuable for cancer research. WIC1 can be utilized in investigations of tumor growth, metastasis, and the overall role of Wnt signaling in oncogenesis. -
Wnt Inhibitor
Gigantol isomer-1 is a bibenzyl compound that functions as a Wnt inhibitor. This compound demonstrates significant therapeutic potential by targeting cancer cell proliferation and survival through modulation of the Wnt/β-catenin signaling pathway. Its capability to disrupt this crucial pathway makes it a valuable tool for research applications focused on cancer biology and therapeutic development. -
WNT1 Inhibitor
SJ26 is a potent Wnt1 inhibitor that exhibits anticancer activity. By targeting and inhibiting the expression of Wnt1, SJ26 disrupts Wnt1-mediated downstream signaling pathways, leading to a reduction in the migratory capacity of cancer cells. This compound is valuable for research focused on cancer progression and the role of Wnt signaling in tumor metastasis. -
Wnt/β-catenin Inhibitor
15-Oxospiramilactone is a diterpene derivative that functions as a Wnt/β-catenin signaling inhibitor. It exhibits significant biological activity by suppressing tumorigenesis in colon cancer cells, making it a valuable reagent for cancer research. This compound is suitable for studies investigating the modulation of the Wnt pathway and its implications in colorectal cancer progression. -
WNT7A Inhibitor/Photosensitizer
WNT7A-IN-1 is a WNT7A inhibitor that disrupts the interaction between WNT7A and its receptor FZD5, leading to the upregulation of MHC-I expression. This compound enhances the expression of MHC-I and phosphorylated p65 while decreasing the levels of active β-catenin. Additionally, WNT7A-IN-1 serves as a photosensitizer in the green spectral region, making it valuable for research in cancer immunotherapy and photodynamic therapy applications. -
Wnt Pathway Inhibitor
Wnt Pathway Inhibitor 5 is a potent inhibitor of the Wnt signaling pathway, exhibiting an IC50 value of less than 0.003 µM. This compound demonstrates significant anti-cancer activity, making it effective against various malignancies such as ovarian teratocarcinoma, breast cancer, osteosarcoma, and head and neck squamous carcinoma. It serves as a valuable tool for researchers investigating the role of Wnt signaling in cancer progression and therapeutic interventions. -
Wnt Activator
XD23 is a potent Wnt activator that functions by downregulating DKK1, thereby enhancing the WNT/β-catenin signaling pathway. This compound demonstrates significant biological activity in osteosarcoma inhibition, making it a valuable tool for research into bone cancer and related signaling mechanisms. Its ability to modulate Wnt signaling opens avenues for investigating therapeutic strategies targeting Wnt-related pathways in various cancers. -
Wnt/β-catenin Pathway Inhibitor
IWP-2-V2 is an analogue of IWP-2 that effectively inhibits the Wnt/β-catenin signaling pathway. This compound plays a significant role in modulating cellular processes related to development and cancer, making it a valuable tool for researchers studying the implications of Wnt signaling in various biological contexts. Its ability to disrupt β-catenin-mediated transcriptional activity positions IWP-2-V2 as a potential candidate for investigations into regenerative medicine and cancer therapy. -
Wnt Signaling Activator
BML-284 hydrochloride is a potent Wnt signaling activator that enhances TCF-dependent transcriptional activity. It demonstrates an effective EC50 of 700 nM, making it suitable for researching Wnt pathway modulation. This compound is valuable for studies related to developmental biology, cancer research, and other fields that investigate the role of Wnt signaling in cellular processes. -
Wnt Pathway Inhibitor
SEN461 is a potent and orally bioavailable inhibitor of the Wnt signaling pathway. This compound demonstrates significant anti-tumor activity, making it a valuable tool for research applications in glioblastoma multiforme (GBM) and other cancers driven by aberrant Wnt pathway activation. Its efficacy in modulating Wnt-related processes highlights its potential for therapeutic development and mechanistic studies in cancer biology. -
Wnt/b-catenin Inhibitor
21H7 is a selective inhibitor of the Wnt/β-catenin signaling pathway. This compound significantly inhibits cell proliferation in hair follicles and demonstrates potent growth suppression of breast and colon cancer cells. Due to its specific targeting of the Wnt/β-catenin pathway, 21H7 serves as a valuable tool in cancer research and therapeutic development. -
β-Catenin Inhibitor
β-Catenin-IN-7 is an inhibitor of β-catenin, specifically disrupting the interaction between β-catenin and Tcf-4. This compound effectively inhibits Wnt-dependent target gene expression, demonstrating significant anti-cancer activity. It is a valuable tool for research applications focused on cancer biology and the Wnt signaling pathway. -
Wnt Signal Inhibitor
Wnt/β-catenin-IN-7 is a Wnt signaling pathway inhibitor with an IC50 of 0.15 μM. This compound effectively disrupts β-catenin-mediated transcriptional activation, making it valuable for investigating the role of Wnt signaling in cancer and fibrosis. Its potent inhibitory activity supports research into therapeutic targets within these pathological conditions. -
β-catenin Inhibitor
PMED-1 is a potent β-catenin inhibitor that effectively diminishes β-catenin activity in hepatoblastoma and various hepatocellular carcinoma (HCC) cell lines, exhibiting an IC50 range of 4.87 to 32 μM. This compound disrupts Wnt signaling by reducing the interaction between β-catenin and CREB binding protein, leading to the inhibition of cell proliferation. PMED-1 is a valuable tool for cancer research, particularly in studies focused on targeting aberrant Wnt signaling pathways. -
Wnt/β-catenin Inhibitor
Wnt/β-catenin-IN-4 is a potent inhibitor of the Wnt/β-catenin signaling pathway. This compound effectively disrupts β-catenin-dependent transcription, making it a valuable tool for investigating the role of Wnt signaling in various biological processes. It is commonly utilized in cancer research, developmental biology, and studies related to stem cell differentiation. -
WNT5A Antagonist
MDGCEL is a WNT5A peptide that functions as an antagonist to WNT5A signaling. It mimics WNT5A, providing utility in research focused on modulating WNT signaling pathways. MDGCEL is valuable in studies investigating developmental biology, cell signaling, and cancer research, where the regulation of WNT5A activity is crucial. -
Hedgehog Inhibitor
Hh Pathway-IN-1 is a potent inhibitor of the Hedgehog (Hh) signaling pathway, acting primarily as a Gli antagonist. With an IC50 value of 1.1 µM in C3H10T1/2 cells, it demonstrates significant inhibition of Hh pathway functionality while sparing Wnt signaling. Hh Pathway-IN-1 exhibits anti-proliferative effects and reduces GLI1 mRNA expression, contributing to its efficacy in inhibiting colony formation in a dose-dependent manner. This compound is valuable for research in developmental biology and cancer therapeutics targeting the Hedgehog pathway. -
Hedgehog Pathway Inhibitor
3-epi-Vitamin D3, also known as Epicholecalciferol, functions as a Hedgehog pathway inhibitor, exhibiting an IC50 value of 39.2 μM in U87MG cell lines. This Vitamin D3 analogue is useful in studies investigating the modulation of the Hedgehog signaling pathway, which plays a critical role in cellular growth and differentiation. 3-epi-Vitamin D3 may have potential applications in cancer research, particularly in contexts where Hedgehog dysregulation is implicated. -
Hedgehog Inhibitor
Hedgehog IN-1 is a potent inhibitor of the Hedgehog signaling pathway, demonstrating an IC50 of 70 nM. This compound effectively blocks Hedgehog protein activity, making it valuable for research into developmental biology and cancer therapeutics. Hedgehog IN-1 is instrumental in studies aimed at understanding the role of the Hedgehog pathway in tumorigenesis and potential therapeutic applications in related disorders. -
Hh-Signaling Pathway Antagonist
SANT 2 is a potent antagonist of the Hedgehog (Hh) signaling pathway, specifically inhibiting the expression of Gli1. This compound has been shown to induce developmental delays in medaka embryos, making it a valuable tool for studying embryonic development. SANT 2 has significant research applications in various malignancies, including Gorlin syndrome, as well as prostate, pancreatic, and breast cancers, thereby aiding in the exploration of targeted therapies for these conditions. -
Hh Pathway Inhibitor
T-1330 is an inhibitor of the Hedgehog (Hh) signaling pathway, specifically targeting the downstream effector Gli1. By effectively reducing Gli1 expression, T-1330 plays a crucial role in modulating Hh pathway activity. This compound is useful in research applications related to developmental biology and cancer therapy, particularly in studies investigating aberrant Hh signaling in various malignancies. -
Smoothened/Hedgehog Antagonist
AZD8542 is a potent Smoothened (SMO) antagonist that effectively disrupts the Hedgehog (Hh) signaling pathway, which is crucial in tumor progression. This compound is particularly relevant in oncology research, focusing on the interactions within the tumor microenvironment and the stroma compartment. AZD8542's ability to inhibit Hh pathway activity makes it a valuable tool in the study of cancer therapies and tumor biology. -
Hedgehog Pathway Antagonist
Smo antagonist M25 is a selective inhibitor of the Smoothened (Smo) receptor within the Hedgehog signaling pathway. By blocking Smo activity, it effectively attenuates the downstream effects of Hedgehog signaling, which plays a crucial role in cell proliferation and differentiation. This compound is primarily utilized in research applications focusing on cancer biology, developmental processes, and potential therapeutic interventions associated with aberrant Hedgehog pathway activation. -
Hedgehog Pathway Inhibitor
Hedgehog IN-2 is a potent inhibitor of the Hedgehog signaling pathway, exhibiting an IC50 value of less than 0.003 μM in C3H10T1/2 cells. This compound effectively disrupts Hedgehog-mediated cellular signaling, making it a valuable tool for studying embryonic development, cancer biology, and regenerative medicine. Its high potency and specificity enable researchers to investigate the role of the Hedgehog pathway in various biological processes and disease states. -
Hedgehog Inhibitor
Hedgehog IN-6 is a potent Hedgehog (Hh) inhibitor that targets the Hh signaling pathway by binding to the cysteine-rich domain (CRD) of Smoothened (Smo). By obstructing the cholesterization of Smo, Hedgehog IN-6 effectively inhibits Hh pathway activation, which is crucial in various cancer types. This compound is valuable for research applications aimed at understanding and manipulating Hh signaling in oncogenesis and developmental biology. -
Hedgehog Pathway Inhibitor
HPP-9 is a Hedgehog Pathway inhibitor designed as a Proteolysis-Targeting Chimera (PROTAC) that effectively degrades BET bromodomains. With a pIC50 of 6.71, HPP-9 exhibits significant antitumor activity. This compound is valuable for research applications focused on cancer biology and the modulation of the Hedgehog signaling pathway. -
Hedgehog Pathway Inhibitor
Hedgehog IN-3 is a potent inhibitor of the Hedgehog signaling pathway, exhibiting an IC50 of 0.01 µM. This compound is primarily utilized in cancer research to investigate the role of Hedgehog-mediated signaling in tumorigenesis and cellular proliferation. Its effectiveness in modulating this pathway makes it a valuable tool for studying various malignancies and developing targeted therapeutic strategies. -
Hedgehog Inhibitor
Hedgehog IN-10 is a potent inhibitor of the Hedgehog signaling pathway, targeting essential components in cellular signaling. This compound demonstrates significant antitumor activity, making it a valuable tool for cancer research. Its ability to modulate Hedgehog signaling contributes to investigations into therapeutic strategies for tumors associated with dysregulated Hedgehog pathway activity. -
Hh Inhibitor
Physalin H is a bioactive compound extracted from Solanum nigrum, functioning as a Hedgehog (Hh) signaling inhibitor. It effectively disrupts GLI1-DNA complex formation and inhibits GLI1 transcription with an IC50 of 0.7 μM. Additionally, Physalin H exhibits cytotoxic effects on PANC1 and DU145 cancer cell lines, demonstrating IC50 values of 5.7 μM and 6.8 μM, respectively. This compound is valuable for research into Hh pathway modulation and cancer therapeutics. -
Hedgehog Pathway Inhibitor
Hedgehog IN-5 is a small molecule inhibitor that targets the Hedgehog signaling pathway. This orally active compound is primarily employed in research pertaining to fibrotic diseases, providing valuable insights into the mechanisms underlying this condition. Its ability to modulate Hedgehog pathway activity makes it a significant tool for exploring therapeutic strategies in related biological contexts. -
Hedgehog Antagonist
Methoxy-SANT-2 is a potent Hedgehog pathway antagonist, demonstrating an IC50 value of 79.8 nM. It effectively inhibits Gli1 reporter gene expression, making it a valuable tool in investigating Hedgehog signaling. This compound is suitable for research applications focused on cancer biology and therapeutic strategies targeting the Hedgehog pathway. -
Hedgehog Inhibitor
Hedgehog IN-4 is a potent inhibitor of the Hedgehog signaling pathway, acting as a benzamide derivative with an IC50 of 0.050 nM. It effectively disrupts Hedgehog-mediated cellular processes, making it valuable for research on developmental biology, cancer, and regenerative medicine. Its ability to modulate this critical pathway allows for exploration into the mechanisms of diseases associated with Hedgehog signaling dysregulation.
